Search tips
Search criteria 


Logo of onclettLink to Publisher's site
Oncol Lett. 2017 February; 13(2): 722–730.
Published online 2016 December 6. doi:  10.3892/ol.2016.5463
PMCID: PMC5351191

MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression


Multidrug resistance (MDR) impedes successful chemotherapy in colorectal carcinoma (CRC) and emerging evidence suggests that microRNAs (miRs) are involved in the development of MDR. In the present study, the role of miR-93-5p in the modulation of drug resistance in CRC was investigated using HCT-8 and MDR HCT-8/vincristine (VCR) cell lines. The results demonstrated upregulated expression of miR-93-5p and MDR protein 1 (MDR1) in HCT-8/VCR cells, compared with the parental HCT-8 cells. Furthermore, cyclin-dependent kinase inhibitor 1A (CDKN1A) was identified as a potential target of miR-93-5p using miR target analysis tools, including PicTar, TargetScan and miRanda. In addition, inhibition of miR-93-5p expression in HCT-8/VCR cells markedly downregulated MDR1 gene expression, upregulated CDKN1A gene expression and induced cell cycle arrest in G1. Conversely, the overexpression of miR-93-5p in HCT-8/VCR cells upregulated MDR1 gene expression, downregulated CDKN1A gene expression and promoted G1/S transition. Furthermore, the in vitro drug sensitivity assay performed suggested that downregulation of miR-93-5p enhanced the sensitivity of HCT-8/VCR cells to VCR, while the upregulation of miR-93-5p decreased the sensitivity of HCT-8 cells to VCR. In conclusion, the results of the present study suggest that miR-93-5p serves a role in the development of MDR through downregulating CDKN1A gene expression in CRC.

Keywords: colorectal carcinoma, multidrug resistance, microRNA-93, multidrug resistance protein 1, cyclin dependent kinase inhibitor 1A


Colorectal carcinoma (CRC) is the third most frequent malignant cancer worldwide (1) and has rapidly increased in incidence in recent years (2). In the United States of America, CRC is the leading cause of cancer-associated morbidity and mortality (3). In China, CRC ranks as the fourth most frequently occurring cancer and the fifth leading cause of cancer-associated mortality (4). Chemotherapy is important in the comprehensive treatment of CRC, and remains the primary treatment for resectable and advanced CRC (5). However, certain patients with CRC who are treated with chemotherapeutics exhibit a poor initial response or gradually develop resistance, a phenomenon known as multidrug resistance (MDR) (6,7). The emergence of MDR is an obstacle to the successful treatment of CRC, leading to poor prognosis, relapse and metastasis of the tumor (8). The underlying molecular mechanisms of chemoresistance are complex and multifactorial, and remain to be completely elucidated. Multiple processes participate in the development of MDR, including those involved in drug transport and metabolism, DNA damage repair and apoptotic regulation (9,10).

Evidence increasingly suggests that microRNAs (miRs) serve an essential role in MDR (1114). miRs are evolutionarily conserved, small non-coding single-stranded RNA molecules of between 19 and 24 nucleotides in length (15,16). The primary function of miRs is to negatively regulate gene expression at the post-transcriptional level, through binding to the 3′ untranslated region of their target mRNA, in part or in full, and subsequently mediating its degradation or inhibiting its translation (17,18). miRs are involved in a number of biological processes, including metabolism, differentiation, proliferation, cell-cycle control and apoptosis (1820). Furthermore, increasing research indicates that miRs function as oncogenes and tumor suppressors, and that the dysregulation of miRs is associated with the development of MDR in various types of cancer (2123). For example, miR-17-5p was demonstrated to be upregulated in chemoresistant CRC cells, which promoted cell invasiveness (24). In addition, miR-508-5p was observed to be downregulated in drug-resistant gastric cancer cells, where its overexpression was demonstrated to reverse drug resistance (25). Various miRs are known to be involved in the regulation of MDR in cancer, including miR-625-3p, miR-1915, miR-200c and miR-203 (2629).

miR-93 belongs to the miR-106b-25 cluster and is located at the human chromosome locus 7q22.1 (30). miR-93 appears to be frequently dysregulated in various types of human cancer, including gastric, ovarian, breast and, in particular, CRC (3135). Furthermore, miR-93 has been demonstrated to participate in the development of MDR in ovarian cancer cells and prolactinomas (36,37). Zhou et al (33) reported that the expression levels of miR-93 were regulated by chemotherapeutics in human colon cancer cells and, thus, may be associated with treatment-resistance in colon cancer. However, to the best of our knowledge, the exact role of miR-93 in the development of MDR in CRC has not yet been investigated and verified. Therefore, in the present study, the role of miR-93-5p in the modulation of drug-resistance in human CRC was examined using HCT-8 and multidrug-resistant HCT-8/vincristine (VCR) cell lines. The results of the current study suggest that miR-93-5p overexpression in CRC serves an essential role in the development of MDR, via miR-93-5p negatively regulating the expression of its target gene, cyclin-dependent kinase inhibitor 1A (CDKN1A).

Materials and methods

Cell lines and cultures

The HCT-8 human ileocecal colorectal adenocarcinoma cell line was obtained from the Kunming Cell Bank of the Chinese Academy of Sciences (Kunming, China), while the HCT-8/VCR multidrug-resistant variant was purchased from the Modern Analysis and Testing Center of Central South University (Changsha, China). Cells were maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere containing 5% CO2. A total of 1 µg/ml VCR was added to HCT-8/VCR cell cultures to maintain their MDR phenotype.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of miR-93-5p

Total RNA (40 ng) was extracted from the cultured cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Polyadenylation was subsequently carried out, in which first strand cDNA synthesis was performed using the miRcute miRNA First-strand cDNA Synthesis kit (Tiangen Biotech Co., Ltd., Beijing, China), according to the manufacturer's protocol. The miRcute miRNA qPCR Detection kit (Tiangen Biotech Co., Ltd.) was used for the following RT-qPCR analysis. Briefly, the 20 µl PCR reaction volume included 10 µl 2X miRcute miRNA Premix, 2 µl first strand cDNA, 7.2 µl RNase-free ddH2O, 0.4 µl forward primer (final concentration 200 nM) and 0.4 µl reverse primer (final concentration 200 nM). The reactions were incubated in a 96-well optical plate at 94°C for 2 min, followed by 40 cycles at 94°C for 20 sec and 60°C for 34 sec. The universally expressed U6 small nuclear RNA (snRNA) was used as an internal control for normalization. Primers for miR-93-5p (cat. no. CD201-0041) and U6 (cat. no., CD201-0145) were acquired from Tiangen Biotech Co., Ltd. The 2−ΔΔCq method (38) was used to calculate the relative expression levels of miR-93-5p for each cell line. The treated group included HVT-8 cells, whereas the control group was HCT-8/VCR cells. [increment]Cq was calculated as follows: Average miR-93-5p Cq-average U6 snRNA Cq. [increment][increment]Cq was calculated as the following: [increment]Cq of the treated group-[increment]Cq of the control group. The results are presented as the fold change in expression in HCT-8 cells relative to HCT-8/VCR cells.

miR transfection

The miR-93-5p mimic (cat. no. B01001) and inhibitor (cat. no. B03001), and the corresponding negative control (NC; cat. no. B04001), were designed and chemically synthesized by GenePharma Co., Ltd. (Shanghai, China). HCT-8/VCR and HCT-8 cells were seeded into 6-well plates at a density of 2×105 cells/well and cultured at 37°C for 24 h. A total of 100 pmol miR-93-5p mimic, miR-93-5p inhibitor or NC was transfected into target cells using 5 µl Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.) and Opti-MEM® I reduced serum medium (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.

Bioinformatics method

The following online miRNA target prediction algorithms were used to evaluate the potential target genes of miR-93-5p: PicTar (, TargetScan ( and miRanda (

RT-qPCR of MDR protein 1 (MDR1) and CDKN1A

Total RNA (500 ng) was isolated from the cells using TRIzol® reagent, according to the manufacturer's protocol. cDNA was synthesized using a PrimeScript™ RT reagent kit (cat. no., RR037A; Takara Biotechnology Co., Ltd., Dalian, China). The PCR reaction mix contained 12.5 µl FastStart Universal SYBR Green Master (Roche Diagnostics GmbH, Mannheim, Germany), 0.25 µl forward and reverse primers (final concentration, 300 nM) and 2.5 µl cDNA, made up to a final volume of 25 µl with RNase-free ddH2O. Primers for MDR1, CDKN1A and GAPDH were acquired from GenePharma Co. Ltd. MDR1 (GeneBank accession number, NM_000927.4): 5′-GTTGCTGCTTACATTCAGGTTTC-3′ (sense) and 5′-ACCAGCCTATCTCCTGTCGC-3′ (antisense); CDKN1A (GeneBank accession number, NM_000389.4): 5′-CCTTCCTCATCCACCCCATC-3′ (sense) and 5′-CCCTGTCCATAGCCTCTACTGC-3′ (antisense); GAPDH (GeneBank accession number, NM_001256799.2): 5′-GTCAGCCGCATCTTCTTT-3′ (sense) and 5′-CGCCCAATACGACCAAAT-3′ (antisense). The ABI 7500 real time PCR system with 7500 software version 2.0.6 (Applied Biosystems; Thermo Fisher Scientific, Inc.) was utilized to quantify the expression levels of RNA. The thermocycling conditions for the RT-qPCR were as follows: 50°C for 2 min, 95°C for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 1 min. The expression levels of MDR1, CDKN1A and GAPDH were assessed using the 2−ΔΔCq method, as aforementioned, while GAPDH was used as an internal control.

Western blot analysis

At 48 h following transfection, the cells were washed with 1X PBS and then lysed using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Shanghai, China) for 30 min at 4°C. The protein concentration was measured using a bicinchoninic acid protein assay kit (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China), following the manufacturer's protocol, and 30 µg protein was separated by 10% SDS-PAGE for western blot analysis. Once the proteins were transferred to a polyvinylidene difluoride membrane (Merck Millipore, Darmstadt, Germany), the membrane was incubated in bovine serum albumin blocking buffer (Beijing Solarbio Science & Technology Co., Ltd.) at room temperature for 1 h and washed with Tris-buffered saline and Tween-20 (TBST; Beijing Solarbio Science & Technology Co., Ltd.) three times (5 min/time). Monoclonal antibodies specific to MDR1 (cat. no. 13342; dilution, 1:1,000), CDKN1A (cat. no. 2947; dilution, 1:1,000) or β-actin (cat. no. 12620; dilution, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) were utilized and the membranes were incubated overnight at 4°C. β-actin was used as the internal control. Following washing three times with TBST (5 min/time), the membrane was probed with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (cat. no. KC-RB-035; dilution, 1:5,000; KangChen Bio-tech, Shanghai, China) for 1 h at room temperature. Subsequently, the membranes were washed with TBST three times (5 min/time), ECL Plus Western Blotting Substrate (Pierce; Thermo Fisher Scientific, Inc.) was used to identify protein bands and ImageJ software (National Institutes of Health, Bethesda, MD, USA; version 1.48) was used to quantify their intensity.

Rhodamine 123 (Rh-123) was used to measure MDR1 efflux

Rh-123 is a fluorescent dye (Dojindo Molecular Technologies, Inc., Rockville, MD, USA) that binds to MDR1, which is an established tool to examine the transport activity of MDR1 (39). A total of 5×105 cells were incubated with 20 µM Rh-123 for 1 h at 37°C. Following incubation, cells were washed three times with PBS to remove free Rh-123 from the medium. Cells were subsequently kept in Rh-123-free medium at 37°C. The intracellular fluorescence intensity of the remaining Rh-123 was examined using fluorescence-activated cell sorting with a flow cytometer (FC500; Beckman Coulter, Inc., Brea, CA, USA).

In vitro drug sensitivity assay

A total of 24 h following miR transfection, the cells were seeded into 96-well plates at a density of 3×103 cells/well. Following cellular adhesion, VCR was added to provide the following final concentrations: 0.001, 0.01, 0.1, 1, 10 and 100 times the peak human plasma concentration. The peak serum concentration of VCR was taken to be 0.5 µg/ml, as previously determined by Zhu et al (40). The Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Rockville, MD, USA) assay was performed to assess cell viability at 72 h following miR transfection. The absorbance of each well at 450 nm was detected using the ELx808™ Absorbance Reader with Gen5 software version 2.00.20 (BioTek Instruments, Inc., Winooski, VT, USA). Furthermore, the half-maximal inhibitory concentration (IC50) of VCR on cell viability was determined by calculating the dose-response curve.

Cell cycle assay

A total of 72 h following miR transfection, HCT-8/VCR cells were harvested by centrifugation at 300 × g for 10 min at room temperature. Cells were washed three times with cold PBS and fixed in ice-cold 75% ethanol at 4°C overnight. Fixed cells were subsequently rehydrated in 200 µl ice-cold PBS and treated with 20 µl RNase (Yeasen Biotech Co., Ltd., Shanghai, China) for 30 min. Subsequently, the cell samples were treated with 400 µl propidium iodide staining solution, followed by incubation at 4°C for 30 min in the dark. The cell cycle distribution for each sample was estimated using FlowJo software (version 7.6.1; FlowJo, LLC, Ashland, OR, USA), according to the manufacturer's protocol.

Statistical analysis

The data are presented as the mean ± standard deviation of triplicate results. The difference between means was statistically analyzed using a two-tailed Student's t-test when 2 groups were compared, or one-way analysis of variance (ANOVA) when >2 groups were compared. In ANOVA, post hoc tests were used for multiple comparisons as follows: The Fisher's least significant difference and Students-Newman-Keuls methods were applied if equal variances were assumed; the Games-Howell method was applied if equal variances were not assumed. All statistical analyses were performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.


Expression of miR-93-5p and MDR1 in HCT-8 and HCT-8/VCR CRC cells

miR-93-5p and MDR1 mRNA expression levels were examined in HCT-8 and HCT-8/VCR cell lines using RT-qPCR, and MDR1 protein levels were evaluated using western blotting. The results of the present study demonstrated that the relative expression of miR-93-5p was significantly increased in HCT-8/VCR cells, compared with HCT-8 cells (P<0.001; Fig. 1A). In addition, the relative expression levels of MDR1 mRNA were significantly increased in HCT-8/VCR cells, compared with the parental HCT-8 cells (P=0.001; Fig. 1B). Similarly, MDR1 protein levels were increased in HCT-8/VCR cell lines, compared with HCT-8 cell lines (P=0.011; Fig. 1C and D).

Figure 1.
(A) Relative expression levels of miR-93-5p in HCT-8 and HCT-8/VCR cells, detected using RT-qPCR. Relative expression of miR-93-5p was normalized to U6 small nuclear RNA. (B) Relative expression levels of MDR1 mRNA in HCT-8 and HCT-8/VCR cells, as measured ...

miR-93-5p regulates the expression of MDR1

To investigate whether miR-93-5p is involved in the regulation of MDR1 gene expression, HCT-8/VCR cells were transfected with the miR-93-5p mimic, miR-93-5p inhibitor or the NC. MDR1 mRNA and protein expression levels were evaluated using RT-qPCR and western blotting, respectively. The results indicated that MDR1 mRNA (P<0.001; Fig. 2A) and protein (P<0.001; Fig. 2B and C) expression levels were significantly decreased in HCT-8/VCR cells transfected with the miR-93-5p inhibitor, compared with the NC-transfected cells. Conversely, MDR1 mRNA (P<0.001; Fig. 2A) and protein (P<0.001; Fig. 2B and C) expression levels were significantly increased in HCT-8/VCR cells transfected with the miR-93-5p mimic, compared with the NC-transfected cells.

Figure 2.
(A) Relative expression levels of MDR1 mRNA in HCT-8/VCR cells transfected with miR-93-5p mimic, miR-93-5p inhibitor or a NC were measured using the reverse transcription-quantitative polymerase chain reaction 48 h following the transfection. GAPDH was ...

Dysregulation of miR-93-5p is associated with the transport activity of MDR1

In order to verify the role of miR-93-5p in the regulation of MDR1 expression, MDR1 transport activity was assessed by measuring the intracellular accumulation of Rh-123, whereby increased MDR1 transport activity is indicated by decreased intracellular Rh-123 fluorescence. As presented in Fig. 3A and B, the fluorescence intensity of Rh-123 was significantly increased in HCT-8/VCR cells transfected with the miR-93-5p inhibitor, compared with cells transfected with the NC (P<0.001). Conversely, HCT-8/VCR cells transfected with the miR-93-5p mimic exhibited significantly decreased Rh-123 fluorescence intensity, compared with the cells transfected with the NC (P=0.034; Fig. 3A and B). These results were consistent with those of the RT-qPCR and western blot analyses.

Figure 3.
miR-93-5p promotes efflux of Rh-123 in HCT-8/VCR cells. (A) The release index of Rh-123 in HCT-8/VCR cells transfected with miR-93-5p mimic, miR-93-5p inhibitor or a NC was determined following 1 h incubation with 20 µM Rh-123. The fluorescence ...

miR-93-5p modulates the sensitivity of human CRC cells to anti-cancer drugs

To determine whether miR-93-5p is directly involved in the development of drug resistance in human CRC cells, the sensitivity of miR-93-5p mimic-transfected HCT-8 and miR-93-5p inhibitor-transfected HCT-8/VCR cells to increasing concentrations of VCR was examined using a CCK-8 assay. miR-93-5p inhibitor-transfected HCT-8/VCR cells exhibited enhanced sensitivity to VCR (IC50, 4.472 µM), compared with the NC-transfected cells (IC50, 100.7 µM; Fig. 3C). Conversely, the sensitivity of miR-93-5p mimic-transfected HCT-8 cells to VCR (IC50, 11.37 µM) was decreased, compared with the NC-transfected cells (IC50, 0.8884 µM; Fig. 3C). The results of the present study indicate that miR-93-5p has an important role in the regulation of MDR phenotypes in human CRC cells.

CDKN1A as a target of miR-93-5p repression

CDKN1A, also known as p21Cip1, is a key member of the Cip/Kip family of cyclin kinase inhibitors and acts as a regulator of cell cycle progression in G1 (41,42). CDKN1A was identified as a potential target of miR-93-5p using the miR target analysis tools PicTar, TargetScan and miRanda (43,44). In order to evaluate whether miR-93-5p modulates MDR through the downregulation of CDKN1A gene expression in human CRC cells, HCT-8/VCR cells were transfected with a miR-93-5p mimic, miR-93-5p inhibitor or an NC. A total of 72 h following transfection, RT-qPCR and western blot analyses were performed to evaluate the expression levels of CDKN1A mRNA and protein, respectively. Significant upregulation of CDKN1A mRNA expression levels was observed in the miR-93-5p inhibitor-transfected cells (P<0.001), and significant downregulation of CDKN1A mRNA expression levels was observed in the miR-93-5p mimic-transfected cells (P<0.0001), compared with NC-transfected cells (Fig. 4A). Furthermore, as presented in Fig. 4B and C, transfection with the miR-93-5p mimic significantly reduced HCT-8/VCR cell CDKN1A protein expression levels (P<0.001), while transfection with the miR-93-5p inhibitor significantly increased CDKN1A protein expression levels (P<0.001), compared with transfection of the NC siRNA.

Figure 4.
(A) Relative expression levels of CDKN1A mRNA in HCT-8/VCR cells transfected with miR-93-5p mimic, miR-93-5p inhibitor or an NC were determined using the reverse transcription-quantitative polymerase chain reaction 48 h following transfection. GAPDH was ...

Inhibition of miR-93-5p induces G1 cell cycle arrest in HCT-8/VCR cells

A total of 72 h following transfection with the miR-93-5p mimic or inhibitor, the cell cycle distribution of HCT-8/VCR cells was analyzed using flow cytometry. As presented in Fig. 5A, the percentage of cells in G1 was significantly increased in the inhibitor-treated group, compared with the NC group (48.94±0.64% vs. 36.57±1.81%; P<0.001). Conversely, the percentage of cells in G2/M and S was significantly decreased in the inhibitor-treated group, compared with the NC group (51.06±0.65% vs. 63.43±1.81%; P<0.001). Furthermore, transfection with the miR-93-5p mimic significantly decreased the proportion of cells in G1 phase, compared with the NC group (25.63±0.39% vs. 36.57±1.81%; P<0.001). By contrast, the proportion of cells in the G2/M and S phase significantly increased, compared with the NC (74.37±0.39% vs. 63.43±1.81%; P<0.001). The results of the present study suggest that repression of miR-93-5p induces G1 arrest, and inhibits cell proliferation and G1/S transition.

Figure 5.
(A) Cell cycle distribution of HCT-8/VCR cells transfected with miR-93-5p mimic, miR-93-5p inhibitor or an NC was analyzed 72 h following transfection using flow cytometry. Overexpression of miR-93-5p induced cell cycle progression in HCT-8/VCR cells. ...


MDR involves simultaneous resistance to multiple anti-cancer drugs and is, therefore, a frequent cause of chemotherapy failure, particularly in CRC (7,45). Increasing evidence has revealed that aberrant miR expression contributes to the development of MDR in CRC (46). Valeri et al (47) reported that CRC cells with upregulated miR-21 expression exhibited significantly reduced sensitivity to therapeutics. In addition, Zhang et al (48) demonstrated that miR-153 overexpression led to oxaliplatin and cisplatin resistance in CRC. Furthermore, Xu et al (27) observed that miR-1915 was downregulated in drug-resistant HCT-116 and L-OHP cell lines, and that the upregulation of miR-1915 sensitized cells to anticancer drugs by reducing B-cell lymphoma-2 protein expression. However, the underlying mechanisms of drug resistance in CRC remain unclear. Additionally, a previous study indicated that miR-93 is dysregulated in human colon cancer and correlates with treatment resistance (33). In the present study, the role of miR-93-5p was further examined and observed to modulate MDR in human CRC cells by downregulating CDKN1A mRNA and protein expression.

Recently, miR mimic technology has proven to be a powerful tool in the study of specific miR functions, due to its stability and lack of off-target effects (49). In the present study, a synthetic miR mimic and inhibitor were used to investigate the role of miR-93-5p in chemoresistance in CRC. The results indicated that the expression of miR-93-5p was significantly increased in the drug-resistant HCT-8/VCR cell line, compared with the parental HCT-8 cell line, and that this was accompanied by significantly increased MDR1 expression. Further investigation demonstrated that transfection of HCT-8/VCR cells with an miR-93-5p inhibitor significantly downregulated MDR1 expression, increased Rh-123 fluorescence intensity, enhanced sensitivity to VCR and induced G1 cell cycle arrest, compared with the miR-93-5p mimic and NC-transfected cells. Conversely, transfection of HCT-8 cells with an miR-93-5p mimic reduced sensitivity to VCR compared with the NC-transfected cells. The results of the present study suggest that the role of miR-93-5p in MDR is indirectly associated with modulation of MDR1 expression and cell cycle control.

At present, the most commonly studied underlying mechanism of MDR is the overexpression of efflux transporters, particularly MDR1 (13). MDR1 is a member of the ATP binding cassette transporter superfamily, which may reduce the accumulation of intracellular chemotherapeutics in tumor cells through the efflux of anti-cancer drugs (13). A number of miRs have been demonstrated to participate in the modulation of drug resistance by regulating the expression of MDR1, including miR-27a, miR-451, miR-298, miR-9 and miR-122 (5053). In addition to MDR1 overexpression, regulation of the cell cycle in tumors has been indicated to be involved in the development of MDR (54). Huang et al (55) demonstrated that cell cycle regulation has an important role in chemoresistance in human ovarian cancer. The present study investigated the role of MDR1 and miR-93-5p-mediated cell cycle modulation in CRC chemoresistance.

In order to further elucidate the underlying mechanisms of MDR, factors involved in the direct regulation of MDR1 and miR-93-5p-mediated cell cycle progression were examined. Using PicTar, TargetScan and miRanda, CDKN1A was identified as a potential target of miR-93-5p. CDKN1A is a cyclin-dependent kinase inhibitor that belongs to the Cip/Kip family of cyclin kinase inhibitors and negatively modulates cell cycle progression (41). CDKN1A inhibits the activity of cyclin/cyclin-dependent kinase complexes, thus regulating G1/S cell cycle progression (42). CDKN1A causes G1 cell cycle arrest when overexpressed in cells (56). Furthermore, CDKN1A has been demonstrated to contribute to the chemotherapeutic response of cancer cells. Ding et al (57) observed that overexpression of CDKN1A sensitized human osteosarcoma cells to cisplatin. Qin et al (58) reported that upregulated expression of CDKN1A significantly increased the chemosensitivity of hepatoma cells to cisplatin. Abukhdeir et al (59) concluded that loss of CDKN1A function was associated with poor treatment response to tamoxifen in human breast cancer cells. In addition, Ziller et al (60) demonstrated that CDKN1A was involved in drug resistance in ovarian carcinoma cells.

The present study aimed to validate the modulation of CDKN1A by miR-93-5p. Significantly elevated CDKN1A mRNA and protein expression was observed in miR-93-5p inhibitor-transfected HCT-8/VCR cells, compared with NC-transfected cells. Concurrently, transfection of HCT-8/VCR cells with an miR-93-5p inhibitor induced G1 cell cycle arrest and increased sensitivity to VCR. The results of the present study suggest that CDKN1A is a direct target of miR-93-5p and that repression of miR-93-5p restores CDKN1A function. Furthermore, Wu et al (37) demonstrated that aberrant expression of miR-93 was negatively associated with CDKN1A protein expression. In addition, luciferase reporter assays have identified CDKN1A to be a direct target of miR-93 (37,61,62). The results of the present study indicate that miR-93-5p participates in the development of MDR by downregulating the expression of CDKN1A, subsequently modulating MDR1 expression and cell cycle progression.

In conclusion, the results of the present study demonstrate that miR-93-5p is upregulated in drug-resistant CRC cells and that downregulation of miR-93-5p results in increased chemotherapeutic sensitivity. This suggests that miR-93-5p modulates MDR in CRC. Inhibition of miR-93-5p was found to downregulate MDR1 expression, increase intracellular chemotherapeutic drug concentration and increase the proportion of cells in G1, through upregulating CDKN1A mRNA and protein expression. Therefore, the present study indicates that miR-93-5p is a novel therapeutic target for the treatment of CRC with MDR.


The present study was supported by The National Natural Science Foundation of China (grant nos. 81260316 and 81260335). Furthermore, the authors thank Professor Lian-Ying Ge (Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China) for her advice, technical assistance and critical reading of this manuscript.


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254. [PubMed] [Cross Ref]
2. Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol. 2005;6:871–876. doi: 10.1016/S1470-2045(05)70422-8. [PubMed] [Cross Ref]
3. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117. doi: 10.3322/caac.21220. [PubMed] [Cross Ref]
4. Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol. 2005;11:4685–4688. doi: 10.3748/wjg.v11.i30.4685. [PMC free article] [PubMed] [Cross Ref]
5. Henaine AM, Chahine G, Salameh P, Elias E, Massoud M, Hartmann D, Aulagner G, Armoiry X. MANAGEMENT OF METASTATIC COLORECTAL CANCER: Current Treatments and New Therapies. J Med Liban. 2015;63:218–227. [PubMed]
6. Kozovska Z, Gabrisova V, Kucerova L. Colon cancer: Cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 2014;68:911–916. doi: 10.1016/j.biopha.2014.10.019. [PubMed] [Cross Ref]
7. Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol. 2014;89:217–230. doi: 10.1016/j.critrevonc.2013.08.015. [PubMed] [Cross Ref]
8. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–584. doi: 10.1038/nrc2167. [PubMed] [Cross Ref]
9. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004;4:1347–1356. doi: 10.2174/1568026043387746. [PubMed] [Cross Ref]
10. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27:5959–5974. doi: 10.1038/onc.2008.274. [PubMed] [Cross Ref]
11. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–391. doi: 10.1007/s12032-010-9797-4. [PubMed] [Cross Ref]
12. Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, Bai L, Zhang XB. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013;238:1024–1032. doi: 10.1177/1535370213497321. [PubMed] [Cross Ref]
13. Xia H, Hui KM. Mechanism of cancer drug resistance and the involvement of noncoding RNAs. Curr Med Chem. 2014;21:3029–3041. doi: 10.2174/0929867321666140414101939. [PubMed] [Cross Ref]
14. Zong C, Wang J, Shi TM. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol. 2014;35:12151–12156. doi: 10.1007/s13277-014-2520-x. [PubMed] [Cross Ref]
15. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. [PubMed] [Cross Ref]
16. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: Profile, profile, profile. Int J Cancer. 2008;122:969–977. doi: 10.1002/ijc.23343. [PubMed] [Cross Ref]
17. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–524. doi: 10.1101/gad.1399806. [PubMed] [Cross Ref]
18. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 2008;9:102–114. doi: 10.1038/nrg2290. [PubMed] [Cross Ref]
19. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94:776–780. doi: 10.1038/sj.bjc.6603023. [PMC free article] [PubMed] [Cross Ref]
20. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28:2–12. doi: 10.1093/carcin/bgl185. [PubMed] [Cross Ref]
21. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353:1768–1771. doi: 10.1056/NEJMp058190. [PubMed] [Cross Ref]
22. Cho WC. OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60. doi: 10.1186/1476-4598-6-60. [PMC free article] [PubMed] [Cross Ref]
23. Xue J, Niu J, Wu J, Wu ZH. MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol. 2014;5:730–743. doi: 10.5306/wjco.v5.i4.730. [PMC free article] [PubMed] [Cross Ref]
24. Fang L, Li H, Wang L, Hu J, Jin T, Wang J, Yang BB. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014;5:2974–2987. doi: 10.18632/oncotarget.1614. [PMC free article] [PubMed] [Cross Ref]
25. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33:3267–3276. doi: 10.1038/onc.2013.297. [PubMed] [Cross Ref]
26. Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, et al. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637–646. doi: 10.1016/j.molonc.2013.02.016. [PubMed] [Cross Ref]
27. Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 2013;52:70–78. doi: 10.1002/mc.21832. [PubMed] [Cross Ref]
28. Sui H, Cai GX, Pan SF, Deng WL, Wang YW, Chen ZS, Cai SJ, Zhu HR, Li Q. miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. Mol Cancer Ther. 2014;13:3137–3151. doi: 10.1158/1535-7163.MCT-14-0167. [PubMed] [Cross Ref]
29. Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X, Guo H. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015;6:8914–8928. doi: 10.18632/oncotarget.3563. [PMC free article] [PubMed] [Cross Ref]
30. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol. 2010;37:1315–1321. [PubMed]
31. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–2695. doi: 10.1158/1078-0432.CCR-07-1731. [PubMed] [Cross Ref]
32. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, Kim VN. Functional links between clustered microRNAs: Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37:1672–1681. doi: 10.1093/nar/gkp002. [PMC free article] [PubMed] [Cross Ref]
33. Zhou J, Zhou Y, Yin B, Hao W, Zhao L, Ju W, Bai C. 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol Rep. 2010;23:121–128. [PubMed]
34. Yu XF, Zou J, Bao ZJ, Dong J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol. 2011;17:4711–4717. doi: 10.3748/wjg.v17.i42.4711. [PMC free article] [PubMed] [Cross Ref]
35. Liu S, Patel SH, Ginestier C, Ibarra I, MartinTrevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 2012;8:e1002751. doi: 10.1371/journal.pgen.1002751. [PMC free article] [PubMed] [Cross Ref]
36. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012;586:1279–1286. doi: 10.1016/j.febslet.2012.03.006. [PubMed] [Cross Ref]
37. Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, Chen YX, Su ZP, Shang HB, Yang WL, et al. MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol Cell Endocrinol. 2014;395:10–18. doi: 10.1016/j.mce.2014.07.014. [PubMed] [Cross Ref]
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [PubMed] [Cross Ref]
39. Zhu H, Cai C, Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett. 2004;576:369–374. doi: 10.1016/j.febslet.2004.09.041. [PubMed] [Cross Ref]
40. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012;69:723–731. doi: 10.1007/s00280-011-1752-3. [PubMed] [Cross Ref]
41. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805–816. doi: 10.1016/0092-8674(93)90499-G. [PubMed] [Cross Ref]
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701–704. doi: 10.1038/366701a0. [PubMed] [Cross Ref]
43. Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, Li Q, Han Z, Wang D, Wei H, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating. Tumour Biol. 2015;36:1701–1710. doi: 10.1007/s13277-014-2771-6. [PubMed] [Cross Ref]
44. Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011;43:217–225. doi: 10.1093/abbs/gmq125. [PubMed] [Cross Ref]
45. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010;46:308–316. doi: 10.1007/s12033-010-9321-2. [PubMed] [Cross Ref]
46. Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 2015;48:503–510. doi: 10.1111/cpr.12202. [PubMed] [Cross Ref]
47. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) Proc Natl Acad Sci USA. 2010;107:21098–21103. doi: 10.1073/pnas.1015541107. [PubMed] [Cross Ref]
48. Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73:6435–6447. doi: 10.1158/0008-5472.CAN-12-3308. [PMC free article] [PubMed] [Cross Ref]
49. Wang Z. The guideline of the design and validation of miRNA mimics. Methods Mol Biol. 2011;676:211–223. doi: 10.1007/978-1-60761-863-8_15. [PubMed] [Cross Ref]
50. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–588. doi: 10.1016/j.bcp.2008.06.007. [PMC free article] [PubMed] [Cross Ref]
51. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011;310:160–169. [PubMed]
52. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180:2490–2503. doi: 10.1016/j.ajpath.2012.02.024. [PubMed] [Cross Ref]
53. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013;2:e126. doi: 10.1038/mtna.2013.60. [PMC free article] [PubMed] [Cross Ref]
54. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 1999;14:169–177. [PubMed]
55. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, et al. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol. 2010;136:447–456. doi: 10.1007/s00432-009-0675-4. [PubMed] [Cross Ref]
56. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25:52–58. doi: 10.1097/CCO.0b013e32835b639e. [PubMed] [Cross Ref]
57. Ding Y, Wang Y, Chen J, Hu Y, Cao Z, Ren P, Zhang Y. p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumour Biol. 2014;35:3119–3123. doi: 10.1007/s13277-013-1404-9. [PubMed] [Cross Ref]
58. Qin LF, Ng IO. Exogenous expression of p21 (WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett. 2001;172:7–15. doi: 10.1016/S0304-3835(01)00701-7. [PubMed] [Cross Ref]
59. Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA. 2008;105:288–293. doi: 10.1073/pnas.0710887105. [PubMed] [Cross Ref]
60. Ziller C, Lincet H, Muller CD, Staedel C, Behr JP, Poulain L. The cyclin-dependent kinase inhibitor p21 (cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett. 2004;212:43–52. doi: 10.1016/j.canlet.2004.03.048. [PubMed] [Cross Ref]
61. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28:2167–2174. doi: 10.1128/MCB.01977-07. [PMC free article] [PubMed] [Cross Ref]
62. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J. 2011;30:823–834. doi: 10.1038/emboj.2011.2. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications